Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.72 |
| ▸ | MAOB | P27338 | 8/20 | 0.72 |
| ▸ | TLR4 | O00206 | 7/20 | 0.72 |
| ▸ | TLR2 | O60603 | 7/20 | 0.72 |
| ▸ | FBP1 | P09467 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | BACE1 | P56817 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236394 | 1.00 | MAOA (0.72) | MAOAMAOBTLR4TLR2FBP1 | |
| SCHEMBL509861 | 0.94 | MAOA (0.72) | MAOAMAOBTLR4TLR2FBP1 | |
| SCHEMBL509860 | 0.94 | MAOA (0.72) | MAOAMAOBTLR4TLR2FBP1 | |
| SCHEMBL10245518 | 0.85 | GSK3B (0.62) | MAOAMAOBTLR4TLR2GSK3B | |
| SCHEMBL510223 | 0.84 | MAOA (1.00) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL510222 | 0.84 | MAOA (1.00) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL566003 | 0.84 | MAOB (0.80) | MAOAMAOBTLR4TLR2FBP1 | |
| SCHEMBL566004 | 0.84 | MAOB (0.80) | MAOAMAOBTLR4TLR2FBP1 | |
| SCHEMBL20024692 | 0.82 | LCK (0.77) | MAOAMAOBGSK3BBACE1LCK | |
| SCHEMBL14786203 | 0.82 | LCK (0.77) | MAOAMAOBGSK3BBACE1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2025-03-27 | — | — | US | disclosed |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-11-12 | — | — | US | disclosed |
| EP-3720438-B1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-111698989-B | Heterocyclic substituted pyridine derivatives as antifungal agents | 安普利克斯制药公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-11512079-B2 | Heterocycle substituted pyridine derivative antifungal agents | AMPLYX PHARMACEUTICALS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-06-03 | — | — | US | disclosed |
| WO-2020247804-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| CN-101300250-A | Heterocyclic substituted pyridine derivative and antifungal agent containing the same | EISAI R&D MAN CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-5853713-A | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units | STERLING WINTHROP INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5618528-A | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units | STERLING WINTHROP INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0748226-A1 | BLOCK COPOLYMERS | NYCOMED IMAGING AS (NO) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995022991-A2 | BLOCK COPOLYMERS | NYCOMED IMAGING AS (NO) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | MAOA 1115/4885MAOB 1060/4885TLR4 1918/4885 |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | MAOA 1115/4885MAOB 1060/4885TLR4 1918/4885 |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | MAOA 3364/4885MAOB 3233/4885TLR4 3167/4885 |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | MAOA 1115/4885MAOB 1060/4885TLR4 1918/4885 |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | ERG28, DPM1, CYP51A1 | MAOA 1115/4885MAOB 1060/4885TLR4 1918/4885 |
| US-11512079-B2 | Heterocycle substituted pyridine derivative antifungal agents | ERG28, DPM1, CYP51A1 | MAOA 1115/4885MAOB 1060/4885TLR4 1918/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | MAOA 940/4885MAOB 690/4885TLR4 3571/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | MAOA 3035/4885MAOB 2930/4885TLR4 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.